ABE / RSABE [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-01-03 13:27 (4923 d 05:20 ago) – Posting: # 9782
Views: 3,603

Hi APB!

❝ […] the study […] seems to be on the basis of ISCV in two different meal status. One study is planned to be two way and one as three way. In three way study, the reference will be dosed twice and the test once.


So you are expecting a CVintra >30% in the fed (?) study and want to go for RSABE. I don’t see any reason why the FDA should not accept such an approach. A warning: If you don’t have strong evidence that you deal with a HVD/HVDP (i.e., CVintra < ~40%) power the study for conventional ABE. If by chance the CV is <30% you are not allowed to scale. For details see FDA’s progesterone guidance.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
279 visitors (0 registered, 279 guests [including 13 identified bots]).
Forum time: 19:47 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5